News

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

BRIO-1 clinical trial sowing optimism as a potential therapeutic option.

The collection at the Truhlsen-Marmor Museum of the Eye includes more than 38,000 objects, including rare books, instruments and immersive educational materials.

Researchers have delved into the possibility of cell-based therapy in ophthalmology. By targeting vitreoretinal diseases, they are tackling a range of vision-threatening disorders which often result in severe irreversible vision loss.

Huang and 2 OCT co-inventors were honored this week at the White House with the National Medal of Technology and Innovation.

Several companies including Kiora Pharmaceuticals, Adverum Biotechnologies and Aviceda Therapeutics, will share data at the 2023 meeting in San Francisco, California

The issuance provides patent protection in the U.S. for therapeutics incorporating the optimized ELOVL2 transgene until 2041. The patent is being prosecuted in the European Union and other countries around the globe. The company said the patent adds value to its lead program in dry AMD.

Several companies including, Kiora Pharmaceuticals, Adverum Biotechnologies, and Aviceda Therapeutics, will share data at the meeting. Our team from Ophthalmology Times will also be in attendance.

Technology allows partitioning of sequencing reads into 2 parental genome data sets.

This compound will be evaluated for the treatment of geographic atrophy (GA). The company shared that the first-in-human study is set to commence in 2024.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

According to the company, the clinical trial will assess the safety, efficacy and tolerability of AURN001, a combination cell therapy product.

Physician discusses 5 keys to achieve optimal results for patients

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.

A new, larger 0.6-mm temporary plug is designed with a tapered edge.

The company continues to turn to experts and leaders to support their mission and the development of new products through these appointments.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.

This gene therapy is designed to be a one-time intravitreally therapy that has demonstrated potent efficacy and a favorable safety profile in preclinical studies.

The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.

Collaboration between ophthalmologists, optometrists can boost early detection.

This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina.

According to a lawsuit filed in U.S. District Court in Detroit, a policy requires Henry Ford Health and Henry Ford Medical Group (HFMG) employees to undergo a screening assessment for cognition when they reach the age of 70, again at age 75 and each year after that.

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

The company made this decision after completing phase 2 trials of the drug.

Developing technology may offer marked improvements in surgical precision

The price tag of publishing presents a tricky research barrier